183 related articles for article (PubMed ID: 37535056)
21. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.
Ueno M; Ikeda M; Morizane C; Kobayashi S; Ohno I; Kondo S; Okano N; Kimura K; Asada S; Namba Y; Okusaka T; Furuse J
Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):611-621. PubMed ID: 31109808
[TBL] [Abstract][Full Text] [Related]
22. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial.
Reiss KA; Mick R; Teitelbaum U; O'Hara M; Schneider C; Massa R; Karasic T; Tondon R; Onyiah C; Gosselin MK; Donze A; Domchek SM; Vonderheide RH
Lancet Oncol; 2022 Aug; 23(8):1009-1020. PubMed ID: 35810751
[TBL] [Abstract][Full Text] [Related]
23. Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma.
Patrinely JR; Baker LX; Davis EJ; Song H; Ye F; Johnson DB
Cancer; 2020 Aug; 126(15):3448-3455. PubMed ID: 32463489
[TBL] [Abstract][Full Text] [Related]
24. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.
Jansen YJL; Rozeman EA; Mason R; Goldinger SM; Geukes Foppen MH; Hoejberg L; Schmidt H; van Thienen JV; Haanen JBAG; Tiainen L; Svane IM; Mäkelä S; Seremet T; Arance A; Dummer R; Bastholt L; Nyakas M; Straume O; Menzies AM; Long GV; Atkinson V; Blank CU; Neyns B
Ann Oncol; 2019 Jul; 30(7):1154-1161. PubMed ID: 30923820
[TBL] [Abstract][Full Text] [Related]
25. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
Afzal MZ; Mabaera R; Shirai K
J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
[TBL] [Abstract][Full Text] [Related]
26. Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART).
Wagner MJ; Othus M; Patel SP; Ryan C; Sangal A; Powers B; Budd GT; Victor AI; Hsueh CT; Chugh R; Nair S; Leu KM; Agulnik M; Sharon E; Mayerson E; Plets M; Blanke C; Streicher H; Chae YK; Kurzrock R
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34380663
[TBL] [Abstract][Full Text] [Related]
27. A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better.
Djureinovic D; Weiss SA; Krykbaeva I; Qu R; Vathiotis I; Moutafi M; Zhang L; Perdigoto AL; Wei W; Anderson G; Damsky W; Hurwitz M; Johnson B; Schoenfeld D; Mahajan A; Hsu F; Miller-Jensen K; Kluger Y; Sznol M; Kaech SM; Bosenberg M; Jilaveanu LB; Kluger HM
Mol Cancer; 2023 Nov; 22(1):182. PubMed ID: 37964379
[TBL] [Abstract][Full Text] [Related]
28. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial.
Padrón LJ; Maurer DM; O'Hara MH; O'Reilly EM; Wolff RA; Wainberg ZA; Ko AH; Fisher G; Rahma O; Lyman JP; Cabanski CR; Yu JX; Pfeiffer SM; Spasic M; Xu J; Gherardini PF; Karakunnel J; Mick R; Alanio C; Byrne KT; Hollmann TJ; Moore JS; Jones DD; Tognetti M; Chen RO; Yang X; Salvador L; Wherry EJ; Dugan U; O'Donnell-Tormey J; Butterfield LH; Hubbard-Lucey VM; Ibrahim R; Fairchild J; Bucktrout S; LaVallee TM; Vonderheide RH
Nat Med; 2022 Jun; 28(6):1167-1177. PubMed ID: 35662283
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study.
Yamazaki N; Kiyohara Y; Uhara H; Uehara J; Fujimoto M; Takenouchi T; Otsuka M; Uchi H; Ihn H; Minami H
Cancer Sci; 2017 Jun; 108(6):1223-1230. PubMed ID: 28342215
[TBL] [Abstract][Full Text] [Related]
30. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
Nishijima TF; Shachar SS; Nyrop KA; Muss HB
Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
[TBL] [Abstract][Full Text] [Related]
31. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
D'Angelo SP; Mahoney MR; Van Tine BA; Atkins J; Milhem MM; Jahagirdar BN; Antonescu CR; Horvath E; Tap WD; Schwartz GK; Streicher H
Lancet Oncol; 2018 Mar; 19(3):416-426. PubMed ID: 29370992
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.
Hao C; Tian J; Liu H; Li F; Niu H; Zhu B
Medicine (Baltimore); 2017 Jun; 96(26):e7325. PubMed ID: 28658143
[TBL] [Abstract][Full Text] [Related]
33. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
Rozeman EA; Menzies AM; van Akkooi ACJ; Adhikari C; Bierman C; van de Wiel BA; Scolyer RA; Krijgsman O; Sikorska K; Eriksson H; Broeks A; van Thienen JV; Guminski AD; Acosta AT; Ter Meulen S; Koenen AM; Bosch LJW; Shannon K; Pronk LM; Gonzalez M; Ch'ng S; Grijpink-Ongering LG; Stretch J; Heijmink S; van Tinteren H; Haanen JBAG; Nieweg OE; Klop WMC; Zuur CL; Saw RPM; van Houdt WJ; Peeper DS; Spillane AJ; Hansson J; Schumacher TN; Long GV; Blank CU
Lancet Oncol; 2019 Jul; 20(7):948-960. PubMed ID: 31160251
[TBL] [Abstract][Full Text] [Related]
34. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
[TBL] [Abstract][Full Text] [Related]
35. Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial.
Heinhuis KM; Carlino M; Joerger M; Di Nicola M; Meniawy T; Rottey S; Moreno V; Gazzah A; Delord JP; Paz-Ares L; Britschgi C; Schilder RJ; O'Byrne K; Curigliano G; Romano E; Patah P; Wang R; Liu Y; Bajaj G; Siu LL
JAMA Oncol; 2020 Jan; 6(1):100-107. PubMed ID: 31697308
[TBL] [Abstract][Full Text] [Related]
36. A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia.
Patel SP; Othus M; Chae YK; Dennis MJ; Gordon S; Mutch D; Samlowski W; Robinson WRR; Sharon E; Ryan C; Lopez G; Plets M; Blanke C; Kurzrock R
Clin Cancer Res; 2024 Jan; 30(1):33-38. PubMed ID: 37882676
[TBL] [Abstract][Full Text] [Related]
37. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
38. Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G
Sheng X; Yan X; Chi Z; Si L; Cui C; Tang B; Li S; Mao L; Lian B; Wang X; Bai X; Zhou L; Kong Y; Dai J; Wang K; Tang X; Zhou H; Wu H; Feng H; Yao S; Flaherty KT; Guo J
J Clin Oncol; 2019 Nov; 37(32):2987-2999. PubMed ID: 31403867
[TBL] [Abstract][Full Text] [Related]
39. A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer.
Nadal E; Saleh M; Aix SP; Ochoa-de-Olza M; Patel SP; Antonia S; Zhao Y; Gueorguieva I; Man M; Estrem ST; Liu J; Avsar E; Lin WH; Benhadji KA; Gandhi L; Guba SC; Diaz IA
BMC Cancer; 2023 Jul; 23(1):708. PubMed ID: 37507657
[TBL] [Abstract][Full Text] [Related]
40. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.
Larkin J; Minor D; D'Angelo S; Neyns B; Smylie M; Miller WH; Gutzmer R; Linette G; Chmielowski B; Lao CD; Lorigan P; Grossmann K; Hassel JC; Sznol M; Daud A; Sosman J; Khushalani N; Schadendorf D; Hoeller C; Walker D; Kong G; Horak C; Weber J
J Clin Oncol; 2018 Feb; 36(4):383-390. PubMed ID: 28671856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
